



#### SECURITY AND CONFIDENTIALITY

All information about HIV/AIDS patients is strictly confidential and is collected for legitimate public health purposes. Confidentiality of HIV/AIDS case reports is of critical importance to maintaining effective HIV/AIDS surveillance. Federal, state, and local health departments have implemented procedures and policies to assure the confidentiality and security of HIV/AIDS data. Prior to submitting data to the CDC, all information is de-identified and encrypted using computer encryption software. In addition, strict guidelines govern the release of reports similar to this one, which ensure that HIV/AIDS data are not presented in such a way as to possibly identify any individual with HIV/AIDS. Maintenance of confidentiality and security safeguards are critical for federal funding and are a top priority within the Philadelphia HIV/AIDS Surveillance Unit.

This publication was supported by the Grant or Cooperative Agreement Number, U62PS003959-04, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

#### **PRIMARY AUTHORS**

Chrysanthus Nnumolu, MD, MPH HIV Surveillance Program Manager

Kathleen A. Brady, MD Medical Director/Medical Epidemiologist

Melissa Miller, MPH Epidemiologist

Tanner Nassau, MPH Epidemiologist

#### CONTRIBUTORS AND EDITORS FOR THIS ISSUE:

- HIV Surveillance Staff Samuel Alexis Barbara Allen Maura Boughter-Dornfeld Caroline Eves Shirley Goss Juanita Johnson Violet Lippincott Erika Solomon Niya Spells Ruth Trino
- Data Management Staff Ceciley Bly Makeda Carroll Dana Higgins Antonios Mashas Melissa Miller Tanner Nassau

#### **Suggested Citation**

Philadelphia Department of Public Health,AIDS Activities Coordinating Office Surveillance Report,2016. Philadelphia, PA: City of Philadelphia;September 2017.

# Contents

| Executive Summary   | 4  |
|---|----|
| Outreach  | 8  |
| Definitions   | 8  |
| Care Continuum  | 10 |
| Figure 1: HIV Care Continuum, Philadelphia vs. U.S  | 10 |
| Newly Diagnosed Cases   | 11 |
| Table 1: Newly Diagnosed HIV Disease by Year 2012-2016                                      | 11 |
| Table 2: Newly Diagnosed HIV Disease by Race/Ethnicity                                      | 12 |
| Table 3: Newly Diagnosed HIV Disease by Sex at Birth  | 13 |
| Map 1: Newly Diagnosed HIV by Census Tract  | 14 |
| Table 4: Percentage of Concurrent HIV/AIDS  | 15 |
| Table 5: Incidence Estimates 2013-2015  | 16 |
| HIV/AIDS Diagnoses  | 17 |
| Table 6: AIDS Diagnoses by Year and Selected Characteristics                                | 17 |
| Figure 2: HIV Diagnoses, AIDS Diagnoses, Deaths, and People Living with HIV/AIDS, 1985–2016 | 18 |
| Figure 3: Rates of Newly Diagnosed HIV/AIDS by Transmission Category                        | 18 |
| Persons Living with HIV/AIDS  | 19 |
| Table 7: Persons Living with HIV (non-AIDS) and AIDS Cases                                  | 19 |
| Table 8: Persons Living with HIV/AIDS by Race/Ethnicity                                     | 20 |
| Table 9: Persons Living with HIV/AIDS by Sex at Birth                                       | 21 |
| Table 10: Persons Living with HIV/AIDS by Gender Identity                                   | 22 |
| Table 11: Prevalence Rates of HIV/AIDS by Census Tract                                      | 23 |
| Figure 4: HIV/AIDS Prevalence Rates by Race and Transmission Category                       | 24 |
| Map 2: Persons Living with HIV/AIDS by Census Tract   | 25 |
| Table 12: Cumulative Adult HIV (non-AIDS) cases   | 26 |
| Table 13: Persons Living with HIV and Hepatitis B or C Co-infection                         | 27 |
| Perinatal Exposures   | 28 |
| Table 14: Perinatal Exposures by Selected Demographics and Clinical Characteristics         | 28 |
| Reporting Information   | 29 |

# Executive Summary

The number of newly diagnosed HIV cases has been on a steady decline since the mid-2000s (Figure 2). In addition to these declines, Philadelphia has a similar percentage of HIV-positive individuals in care when compared to national rates. This report highlights these and other notable trends observed through 2016. By collecting, analyzing, and publishing the most recent data available, AACO is helping our partners initiate, target, and focus their outreach, testing, prevention, and care approaches across the city to ensure that resources and efforts are directed to populations in greatest need. The AIDS Activities Coordinating Office (AACO) Surveillance Report is the annual report presenting data on HIV/AIDS cases in the City of Philadelphia. Data in this report includes persons diagnosed through December 31, 2016 and reported through June 30, 2017.

## **HIV Continuum of Care**

The HIV Continuum of Care is a data driven tool focusing on the diagnosis and care of individuals living with HIV. Engaging HIV patients in care is critical to both individual health as well as slowing the spread of the disease. The Continuum highlights the percentage of people living with HIV at various levels of engagement in care. The report highlights various areas in which Philadelphia is exceeding national outcomes.

The Continuum (Figure 1) includes the percentage of people with new diagnoses who were linked to care; the percentage of people who were retained in care; and the percentage of people who were virally suppressed based on all persons living with HIV (both diagnosed and undiagnosed).

Engaging HIV patients in care is critical to both individual health as well as slowing the spread of the disease.

#### NEW DIAGNOSES:



Slightly less than nine out of every ten (87%) people diagnosed with HIV in 2016 were linked to HIV medical care within 3 months of their diagnosis. However, just under half (46%) of all people living with HIV in Philadelphia were retained in HIV medical care in 2016, defined as two or more medical visits at least 90 days apart. In addition, 51% of all people living with HIV in Philadelphia were virally suppressed at their most recent viral load in 2016 (regardless of if their retention in care status).

Identifying new opportunities to improve linkage to care, retention in care, and viral suppression are vital to improving the health of HIV-positive individuals and reducing the rate of HIV transmission.

## Who Is Most Affected?

Individuals aged 13-24 accounted for 24% of all newly diagnosed HIV infections in 2016 (Table 1). Those whose sex at birth was male—76%— and those reported as men who have sex with men (MSM)—56%— made up the largest proportions of new diagnoses.



New AIDS diagnoses in Philadelphia were comprised primarily of males (69%), with heterosexuals (49%), and those aged 50 and older (30%) representing the largest transmission and age categories, respectively (Table 3).

The rate of new HIV diagnoses is higher among MSM (1,005 per 100,000) compared to PWID (122 per 100,000) and high risk heterosexuals (62 per 100,000) (Figure 5). Among people living with HIV/ AIDS infected through 2016, the highest morbidity is among those who were born male (72%), MSM (36%), and those aged 50 and older (51%). Non-Hispanic blacks continue to be affected by HIV more than any other race/ethnicity group; they represent 64% of all newly diagnosed cases, 69% of newly diagnosed AIDS, and 64% of all prevalent cases.

Of all cases newly diagnosed in 2016, 18% were concurrent HIV/AIDS diagnoses (Table 4). Concurrent HIV/AIDS diagnoses represent a missed opportunity for early HIV diagnosis. While the overall number of concurrent diagnoses has gone down since 2012, certain subpopulations have had better outcomes than others. Between 2012 and 2016, concurrent diagnoses among MSM (26% vs 15%) have fallen below the citywide average of 17.9%, but the same is not true for heterosexuals (31% vs 24%).

#### NATIONAL AND INTERNATIONAL **GOALS FOR HIV CARE AND PREVENTION**

The World Health Organization (WHO) established three primary goals for HIV care and prevention to be achieved by the year 2020:

90% of persons living with HIV know of their infection 90% of those living with diagnosed HIV are on antiretroviral therapy (ART) 90% of those on ART are virally suppressed

AACO actively monitors progress towards these goals among Philadelphia residents living with HIV. For more information on the WHO 90-90-90 goals, visit http://www.unaids.org/en/resources/ documents/2017/90-90-90

The U.S. National HIV/AIDS Strategy (NHAS) established the following goals:

#### reduce new HIV infections

improve health care access and HIV-related health outcomes

## reduce HIV-related disparities

AACO and its partners work towards achieving these goals through increasing HIV testing, increasing access to medical care and ART among people living with HIV, increasing condom and pre-exposure prophylaxis (PrEP) use among those at high risk for HIV infection, and increasing the use of syringe exchange programs among people who inject drugs. For more information on NHAS, visit https://www.hiv.gov/federal-response/ national-hiv-aids-strategy/nhas-update

## Identifying and eliminating racial and ethnic disparities in HIV care and prevention is critical to slowing the spread of the HIV epidemic.

## Racial/Ethnic Disparities

Racial/ethnic health disparities in Philadelphia persist and mirror disparities observed across the nation. In 2016, the rates of new HIV diagnoses in Philadelphia were highest among Hispanics (49.8 per 100,000) followed by Non-Hispanic blacks (48.9 per 100,000) and Non-Hispanic whites (11.4 per 100,000) (Table 2). While there was a 21% decrease in newly diagnosed HIV infections among non-Hispanic blacks from 2015 to 2016, there was a 23% increase in newly diagnosed HIV among Hispanics (Table 1). The overall number of reported HIV cases among Non-Hispanic blacks is almost twice that of Non-Hispanic whites and Hispanics combined. Disparities are also evident in HIV Incidence Estimates. In 2015, an estimated 71.2% of new infections for individuals 13 and older occurred among non-Hispanic blacks (Table 5). Identifying and eliminating these disparities is critical to slowing the spread of the HIV epidemic.

## **Estimates of HIV Incidence**

HIV incidence refers to the number of new infections in a given time period. The majority of new infections occurred among men, persons aged 13-24, and MSM (Table 5). An estimated 42.5% of new infections occurred among youth age 13-24 in 2015.

The significant declines in recent HIV infections are due, in part, to decreases in new infections among heterosexuals and people who inject drugs. These estimates provide valuable information on where additional education and prevention efforts are needed.

## Migration

Historically, HIV/AIDS surveillance has been based on geographical location at the time of HIV or AIDS diagnoses. Migrations were assumed to either be negligible or in migration and out migration were assumed to be roughly equal. HIV/AIDS surveillance increasingly focuses on the individuals currently living in a jurisdiction, rather than those diagnosed in the jurisdiction. While Philadelphia has seen roughly 500 to 700 new cases a year for the past several years, the total population of people living with HIV/AIDS in Philadelphia has remained stable due to a proportionate number of individuals moving out of Philadelphia or dying. Thus current residents, rather than those diagnosed locally, are the focus of our in-care and viral suppression measures in the HIV Care Continuum.

## NHAS Developmental Indicators

In December 2016, the National HIV/AIDS Strategy added three developmental indicators:

- increase the percentage of transgender women in HIV medical care who are virally suppressed to at least 90%
- 2 increase the number of adults prescribed PrEP by at least 500%
- decrease stigma among person with diagnosedHIV infection by at least 25%

These are considered developmental indicators because accurately defining and identifying the data available to monitor their progress will continue to change over the next several years. For more information on the NHAS Developmental Indicators, visit https://files.hiv.gov/ s3fs-public/nhas-indicators-supplement-dec-2016.pdf

## **Transgender Persons**

The quality of data on transgender individuals has not improved at the same pace as surveillance data on the overall population. Some of these differences are attributed to the lack of a gender identity variable in the surveillance system and most medical records before 2009, making it difficult to determine gender identity for individuals diagnosed prior to the addition of these variables to the current data system. Furthermore, many transgender persons are misclassified as men who have sex with men.

AACO has partnered with other state and local health departments to request that the CDC make available more resources for HIV prevention and care in transgender and non-binary populations. Additionally, AACO will begin collecting behavioral surveillance data among transgender women. In an attempt to reexamine issues surrounding the quality of transgender data, Table 10 presents demographic information based on gender identity and reclassifies transmission risk reported as MSM and heterosexual contact into one category called sexual contact. Of the nearly 200 transgender women who received HIV medical care in Philadelphia during 2016, 76.4% were virally suppressed. This number is lower than both cis-gender women (82.6%) and cisgender men (85.0%).

Further understanding of the risk behaviors and needs of transgender persons is needed to inform best practices for treatment and prevention in this population. Efforts to improve data on transgender individuals are ongoing.

## PrEP

PrEP uptake in Philadelphia has increased each year since 2014. AACO uses HIV surveillance data to identify neighborhoods within Philadelphia with high rates of new HIV transmissions but no known PrEP providers, then works to identify and train providers in that area whose patients would benefit from PrEP. Currently, there are over 30 health care facilities throughout Philadelphia with providers who prescribe PrEP to individuals at high risk for HIV infection.

In the summer of 2014, 544 HIV negative MSM were interviewed as part of the National HIV Behavioral Surveillance (NHBS) project and 269 (49.4%) reported some knowledge of PrEP. Currently, NHBS is conducting more interviews among MSM and preliminary results suggest PrEP awareness has increased to nearly 70% in HIV negative MSM. NHBS surveys conducted in previous years among high risk heterosexuals and people who inject drugs demonstrated a smaller proportion of each respective risk group had any knowledge of PrEP.

While PrEP can reduce an individual's chances of acquiring HIV, it is not effective when not taken as directed. Adherence to PrEP must be stressed by providers and condom usage must still be encouraged. For more information on PrEP and PrEP providers, visit http://www.phila.gov/health/AmbulatoryHealth/ prep.html

Adherence to PrEP must be stressed by providers and condom usage must still be encouraged.

## Outreach

In 2016, the AIDS Activities and Coordinating Office launched several community outreach campaigns promoting PrEP, condom use, and STD testing.

## A pill a day can keep HIV away



## Enjoy safer sex for free!

Like getting busy with other guys? Get CONDOMS, LUBE, and TEST KITS mailed to you for free! DoYouPhilly.org



# Definitions

AACO (AIDS Activities Coordinating Office): The office within the Philadelphia Department of Public Health responsible for administering the City's HIV/AIDS Programs.

Acute HIV Infection: Acute HIV infection typically describes the interval between the first possible detection of virus by virologic assay and development of a mature antibody response. Signs and symptoms of acute HIV infection can include fever, headache, sore throat, adenopathy, anorexia, and rash and often are develop about 2 weeks after the start of the infection. AIDS (Acquired Immune Deficiency Syndrome): A result of Human Immunodeficiency Virus (HIV) infection, which disables the immune system from effectively fighting numerous opportunistic infections and cancers.

AIAN (American Indiana/ Alaskan Native): A racial/ethnic group.

## CDC (Centers for Disease Control and Prevention):

A federal disease prevention agency, which is part of the U.S. Department of Health and Human Services that provides national laboratory and health and safety guidelines and recommendations; tracks diseases throughout the world; and performs basic research involving laboratory, behavioral science, epidemiology and other studies of disease. **Confidentiality**: Keeping medical information confidential or private.

**Diagnosis:** Determination of the nature of a case of a disease based on signs, symptoms, and laboratory findings during life. A diagnosis of AIDS for an adult is being HIV antibody-positive in addition to having one opportunistic infection, condition, or disease (e.g. wasting syndrome, PCP, Kaposi's sarcoma, CD4 T-lymphocyte count below 200 or 14%).

**Epidemiology:** The branch of medical science that deals with the study of incidence, distribution and control of a disease in a population.

## Know it before you blow it

Like hooking up with other guys? Visit DoYouPhilly.org to get FREE CONDOMS, FREE STD TESTS, and all of the other info you need to stay healthy. So when you are busy doing it, you can do you.





**Gender Identity:** One's innermost concept of self as male or female or both or neither—how individuals perceive themselves and what they call themselves. One's gender identity can be the same or different than the sex assigned at birth.

**HIV (Human Immunodeficiency Virus):** The retrovirus that causes AIDS by infecting the T-helper cells.

**Incidence:** The number or rate of new cases of a disease over defined period of time.

MSM (Men who have sex with men): An HIV/AIDS transmission category. MSM/PWID (Men who have sex with men who are also people who inject drugs): An HIV/AIDS transmission category.

**NHPI (Native Hawaiian/ Pacific Islander):** A racial/ethnic group.

NIR (No Identified Risk): Indicates when documentation is insufficient to assign an HIV/AIDS transmission category based on CDC guidelines.

**Perinatal Transmission of HIV:** Term used to describe the spread of HIV/ AIDS from a mother to her baby that can occur during pregnancy, labor, delivery or breastfeeding; also known as vertical transmission.

**PrEP:** Pre-exposure prophylaxis. Antiretroviral medication taken daily by individuals at increased risk for HIV infection to lower their chances of getting infected. **Prevalence:** Total number of cases of a disease in a population over a period of time.

**PWID (Person/People Who Inject Drugs):** An HIV/AIDS transmission category.

**Risk Behavior:** Used here to describe behaviors that put people at risk of contracting HIV/AIDS.

**Sexual Orientation:** The sexual attraction people feel for others, whether of their own sex, the opposite sex, or both sexes.

**Transmission Category:** A system that classifies cases by possible HIV transmission risk factors or mode(s) of infection; e.g. PWID, MSM/PWID, perinatal transmission, heterosexual contact.

# HIV Care Continuum

#### FIGURE 1

Philadelphia 2016 vs the United States



Philadelphia Data: Philadelphia Department of Public Health, AIDS Activities Coordinating Office

U.S. Data: Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2015. HIV Surveillance Supplemental Report 2017;22(No. 2). http://www.cdc.gov/hiv/library/reports/hivsurveillance.html. Published July 2017. Accessed August 2017.

#### TABLE 1

## By Year and Selected Characteristics (regardless of AIDS status) | 2012-2016

| Bar graphs           |   |                                    |   |                             | Y                              | EAR O                  | FDIAGN        | OSIS         |              |           |          |
|----------------------|---|------------------------------------|---|-----------------------------|--------------------------------|------------------------|---------------|--------------|--------------|-----------|----------|
| percentages          |   |                                    | 2012  |                             | 2013                           |                        | 2014          |              | 2015         |           | 2016     |
|                      |   | Ν                                  | %   | Ν                           | %                              | Ν                      | %             | Ν            | %            | Ν         | %        |
|                      | Total   | 736                                | 100%  | 641                         | 100%                           | 564                    | 100%          | 540          | 100%         | 480       | 100%     |
| Sex at Birth         |   |                                    |   |                             |                                |                        |               |              |              |           |          |
|                      | Female  | 194                                | 26.3%                                       | 123                         | 19.1%                          | 117                    | 20.7%         | 117          | 21.6%        | 117       | 24.3%    |
|                      | Male  | 542                                | 73.6%                                       | 518                         | 80.8%                          | 447                    | 79.2%         | 423          | 78.3%        | 363       | 75.6%    |
| Race/Ethnicity       |   |                                    |   |                             |                                |                        |               |              |              |           |          |
|                      | Black   | 512                                | 69.5%                                       | 478                         | 74.5%                          | 381                    | 67.5%         | 393          | 72.7%        | 309       | 64.3%    |
|                      | Hispanic                                      | 111                                | 15.0%                                       | 71                          | 11.0%                          | 73                     | 12.9%         | 75           | 13.8%        | 92        | 19.1%    |
|                      | White   | 92                                 | 12.5%                                       | 68                          | 10.6%                          | 86                     | 15.2%         | 56           | 10.3%        | 64        | 13.3%    |
|                      | Asian   | 11                                 | 1.4%  | 13                          | 2.0%                           | 12                     | 2.1%          | 10           | 1.8%         | 10        | 2.0%     |
|                      | Multi-race                                    | 7                                  | 0.9%  | 7                           | 1.0%                           | 8                      | 1.4%          | *            | *            | *         | *        |
|                      | Other/Unknov                                  | vn *                               | *   | *                           | *                              | *                      | *             | *            | *            | *         | *        |
| Age Category         |   |                                    |   |                             |                                |                        |               |              |              |           |          |
|                      | 0-12  | *                                  | *   | *                           | *                              | *                      | *             | *            | *            | 0         | 0.0%     |
|                      | 13-19   | 34                                 | 4.6%  | 45                          | 7.0%                           | 31                     | 5.4%          | 34           | 6.2%         | 29        | 6.0%     |
|                      | 20-24   | 155                                | 21.0%                                       | 132                         | 20.5%                          | 110                    | 19.5%         | 99           | 18.3%        | 86        | 17.9%    |
|                      | 25-29   | 114                                | 15.4%                                       | 102                         | 15.9%                          | 87                     | 15.4%         | 96           | 17.7%        | 99        | 20.6%    |
|                      | 30-39   | 147                                | 19.9%                                       | 128                         | 19.9%                          | 121                    | 21.4%         | 131          | 24.2%        | 111       | 23.1%    |
|                      | 40-49   | 154                                | 20.9%                                       | 117                         | 18.2%                          | 95                     | 16.8%         | 86           | 15.9%        | 68        | 14.1%    |
|                      | 50+   | 131                                | 17.7%                                       | 112                         | 17.4%                          | 119                    | 21.0%         | 92           | 17.0%        | 87        | 18.1%    |
| Transmission Risk    |   |                                    |   |                             |                                |                        |               |              |              |           |          |
|                      | MSM   | 304                                | 41.3%                                       | 327                         | 51.0%                          | 288                    | 51.0%         | 309          | 57.2%        | 270       | 56.2%    |
|                      | PWID  | 83                                 | 11.2%                                       | 42                          | 6.5%                           | 40                     | 7.0%          | 30           | 5.5%         | 27        | 5.6%     |
|                      | Heterosexual                                  | 310                                | 42.1%                                       | 250                         | 39.0%                          | 223                    | 39.5%         | 187          | 34.6%        | 162       | 33.7%    |
|                      | MSM/PWID                                      | 10                                 | 1.3%  | 9                           | 1.4%                           | 6                      | 1.0%          | *            | *            | *         | *        |
|                      | Pediatric                                     | *                                  | *   | 6                           | 0.9%                           | *                      | *             | *            | *            | 0         | 0.0%     |
|                      | No Risk Report                                | ed 28                              | 3.8%  | 7                           | 1.0%                           | 6                      | 1.0%          | 9            | 1.6%         | 16        | 3.3%     |
| <b>Co-Infections</b> |   |                                    |   |                             |                                |                        |               |              |              |           |          |
|                      | Hepatitis B                                   | 21                                 | 2.9%  | 25                          | 3.9%                           | 21                     | 3.7%          | 15           | 2.8%         | 6         | 1.3%     |
|                      | Hepatitis C                                   | 112                                | 15.2%                                       | 73                          | 11.4%                          | 63                     | 11.2%         | 76           | 14.1%        | 40        | 8.3%     |
|                      |   |                                    |   |                             | •                              |                        |               |              |              |           |          |
|                      |   |                                    |   |                             |                                |                        |               |              |              |           | -        |
| TOTAL CASES          |   | 73                                 | 36  |                             | 641                            |                        | 564           |              | 540          |           | 480      |
|                      | Notes *Cell size<br>Source Philade<br>Health, | es <6 are<br>Iphia Dep<br>Division | supressed.<br>partment of P<br>of Disease C | Public Heal<br>ontrol, Vira | th, AIDS Act<br>al Hepatitis F | ivities Coc<br>Program | ordinating Of | fice; Philad | delphia Depa | artment o | f Public |

#### TABLE 2

#### By Race/Ethnicity | 2016

Racial/ethnic health disparities persist and mirror disparities observed across the nation. In 2016, the rates of new HIV diagnoses in Philadelphia were highest among Hispanics, followed by Non-Hispanic blacks and Non-Hispanic whites.

|                   |                                      |                      | BLAC                       | СК                 |                  |                         | HISPA                        | NIC                     |                    |         | WHI   | ТЕ |  |
|-------------------|--------------------------------------|----------------------|----------------------------|--------------------|------------------|-------------------------|------------------------------|-------------------------|--------------------|---------|-------|----|--|
|                   |                                      | Ν                    | %                          |                    |                  | N                       | %                            |                         |                    | Ν       | %     |    |  |
|                   | Total                                | 309                  | 100%                       |                    |                  | 92                      | 100%                         |                         |                    | 64      | 100%  |    |  |
| Sex at Birth      |                                      |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
| •                 | Female                               | 78                   | 25.2%                      |                    |                  | 20                      | 21.7%                        |                         |                    | 16      | 25.0% |    |  |
| •                 | Male                                 | 231                  | 74.7%                      |                    |                  | 72                      | 78.2%                        |                         |                    | 48      | 75.0% |    |  |
| Age Category      |                                      |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
|                   | 0-12                                 | 0                    | 0                          |                    |                  | 0                       | 0                            |                         |                    | 0       | 0     |    |  |
|                   | 13-19                                | 24                   | 7.7%                       |                    |                  | *                       | 4.3%                         |                         |                    | *       | 1.5%  |    |  |
|                   | 20-24                                | 64                   | 20.7%                      |                    |                  | 14                      | 15.2%                        |                         |                    | *       | 7.8%  |    |  |
|                   | 25-29                                | 56                   | 18.1%                      |                    |                  | 21                      | 22.8%                        |                         |                    | 13      | 20.3% |    |  |
|                   | 30-39                                | 61                   | 19.7%                      |                    |                  | 27                      | 29.3%                        |                         |                    | 22      | 34.3% |    |  |
|                   | 40-49                                | 45                   | 14.5%                      |                    |                  | 15                      | 16.3%                        |                         |                    | 7       | 10.9% |    |  |
|                   | 50+                                  | 59                   | 19.0%                      |                    |                  | 11                      | 11.9%                        |                         |                    | 16      | 25.0% |    |  |
| Transmission Risk |                                      |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
|                   | MSM                                  | 171                  | 55.3%                      |                    |                  | 56                      | 60.8%                        |                         |                    | 33      | 51.5% |    |  |
|                   | PWID                                 | 6                    | 1.9%                       |                    |                  | 11                      | 11.9%                        |                         |                    | 10      | 15.6% |    |  |
|                   | Heterosexual                         | 121                  | 39.1%                      |                    |                  | 19                      | 20.6%                        |                         |                    | 17      | 26.5% |    |  |
|                   | MSM/PWID                             | *                    | *                          |                    |                  | *                       | *                            |                         |                    | *       | *     |    |  |
|                   | Pediatric                            | 0                    | 0                          |                    |                  | 0                       | 0                            |                         |                    | 0       | 0     |    |  |
|                   | No Risk Reported                     | 9                    | 2.9%                       |                    |                  | *                       | *                            |                         |                    | *       | *     |    |  |
| Total N           |                                      |                      | 30                         | 9                  |                  |                         | 92                           |                         |                    |         | 64    |    |  |
|                   |                                      |                      | BLAC                       | СК                 |                  |                         | HISPA                        | NIC                     |                    |         | WHI   | TE |  |
|                   | 100                                  |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
|                   |                                      |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
|                   | 80                                   |                      | 10                         | 0                  |                  |                         | 40.0                         | 0                       |                    |         |       |    |  |
|                   | 60                                   |                      | 40                         | .9                 |                  |                         | 49.0                         |                         |                    |         |       |    |  |
|                   | 40                                   |                      |                            |                    |                  |                         |                              |                         |                    |         |       |    |  |
| Rate per 100,000  | 20                                   |                      |                            |                    |                  |                         |                              |                         |                    |         | 11.4  | 1  |  |
|                   | Notes *Cell size<br>Source Philadelp | es <6 are<br>hia Dep | e supressed<br>partment of | l. Rates<br>Public | were c<br>Health | alculated<br>, AIDS Act | using the 20<br>ivities Coor | 010 decen<br>dinating ( | nial cen<br>Office | sus dat | a.    |    |  |

#### TABLE 3

#### By Sex at Birth | 2016

Men comprised the majority of all new HIV infections (76%), with the greatest transmission rates among MSM. Women comprised 24% of new infections, with the highest rates among blacks and heterosexuals.

|                   |  |  | FEMA   | LE                            |   |   |   | MA  | LE   |   |                    |
|-------------------|--|--|--|-------------------------------|---|---|---|---|--|---|--------------------|
|                   |  | Ν  | %  |                               |   | Rate †  | Ν   | %   |  | Rate -  | †                  |
|                   | Total  | 117  | 100%   |                               |   | 14.5  | 363   | 100%  |  | 50.4  | 4                  |
| Race/Ethnicity    |  |  |  |                               |   |   |   |   |  |   |                    |
|                   | Black  | 78   | 66.6%  |                               |   | 22.0  | 231   | 63.6%   |  | 79.4  | 4                  |
|                   | Hispanic   | 20   | 17.0%  |                               |   | 21.2  | 72  | 19.8%   |  | 77.3  | 3                  |
|                   | White  | 16   | 13.6%  |                               |   | 5.5   | 48  | 13.2%   |  | 17.6  | 5                  |
|                   | Asian  | *  | *  |                               |   | *   | 9   | 2.4%  |  | 19.4  | 4                  |
|                   | Multi-race   | *  | *  |                               |   | *   | *   | *   |  |   | *                  |
|                   | Other/Unknowr  | า *  | *  |                               |   | *   | *   | *   |  |   | *                  |
| Age Category      |  |  |  |                               |   |   |   |   |  |   |                    |
|                   | 0-12   | 0  | 0  |                               |   | 0   | 0   | 0   |  | (   | C                  |
|                   | 13-19  | 8  | 6.8%   |                               |   | 10.6  | 25  | 6.8%  |  | 32.5  | 5                  |
|                   | 20-24  | 17   | 14.5%  |                               |   | 23.9  | 78  | 21.4%   |  | 109.6   | 5                  |
|                   | 25-29  | 30   | 25.6%  |                               |   | 28.3  | 82  | 22.5%   |  | 126.9   | Э                  |
|                   | 30-39  | 23   | 19.6%  |                               |   | 22.9  | 81  | 22.3%   |  | 82.3  | 3                  |
|                   | 40-49  | 35   | 29.9%  |                               |   | 13.8  | 45  | 12.3%   |  | 48.9  | Э                  |
|                   | 50+  | *  | *  |                               |   | *   | 52  | 14.3%   |  | 27.2  | 2                  |
| Transmission Risk |  |  |  |                               |   |   |   |   |  |   |                    |
|                   | MSM  | -  | -  |                               |   | -   | 270   | 74.3%   |  | 804.8   | 3                  |
|                   | PWID   | 13   | 11.1%  |                               |   | N/A   | 14  | 3.8%  |  | N/A   | 4                  |
|                   | Heterosexual   | 92   | 78.6%  | _                             |   | 57.2  | 70  | 19.2%   |  | 62.0  | )                  |
|                   | MSM/PWID   | -  | -  |                               |   | -   | *   | *   |  |   | *                  |
|                   | Pediatric  | *  | *  |                               |   | N/A   | 0   | 0   |  | N/A   | 4                  |
|                   | No Risk Reporte  | d 12   | 10.2%  |                               |   | N/A   | *   | *   |  | N/A   | 4                  |
| Total N           |  |  | <b>117</b>   | 7                             |   |   |   | 30  | 53   |   |                    |
|                   | Notes *Cell siz<br>† Rates<br>calcula<br>calcula<br>Comm<br>Source Philade | es <6 are su<br>for age and<br>ated using e<br>ated using t<br>nunity Surve<br>elphia Depa | r E IVI A<br>upressed.<br>race/ethnic<br>estimates of<br>he number of<br>ey.<br>rtment of Pu | ity by s<br>MSM a<br>of indiv | sex at l<br>activity<br>viduals<br>ealth, v | birth were calcula<br>y among males 13<br>18 and older livir<br>AIDS Activities C | ated using the 20<br>3 and older in th<br>ng below the fed<br>coordinating Offi | D10 decenn<br>e last 5 year<br>eral poverty<br>ce | ial census.<br>s. Heteroso<br>v level from | MSM rates we<br>exual rates wer<br>the 2010 Ame | re<br>re<br>ericai |



| ( | Cases     |
|---|-----------|
|   | Diagnosed |
| - | Newly     |

TABLE 4

# Concurrent HIV/AIDS, Demographics and Transmission Risk | 2012-2016

|                   | ;     |               |               |                |            | 0             | L<br>5      |            |          |               |                | -<br> <br>     |             |             |                |               |             |              |                |              |
|-------------------|-------|---------------|---------------|----------------|------------|---------------|-------------|------------|----------|---------------|----------------|----------------|-------------|-------------|----------------|---------------|-------------|--------------|----------------|--------------|
|                   |       | 20            | 12            |                |            | 20            | 113         |            |          | 20.           | 14             |                |             | 20,         | 5              |               |             | 20.          | 16             |              |
|                   | Conct | on-<br>urrent | Conct<br>HIV/ | urrent<br>AIDS | Concu      | on-<br>urrent | Conc<br>HIV | AIDS       | Conc     | on-<br>urrent | Concu<br>HIV// | Irrent<br>AIDS | No<br>concu | n-<br>rrent | Concu<br>HIV// | rrent<br>AIDS | No<br>concu | n-<br>irrent | Concu<br>HIV/A | rrent<br>IDS |
|                   | z     | Col %         | z             | Col %          | z          | Col %         | z           | Col %      | z        | Col %         | z              | Col %          | z           | Col %       | z              | Col %         | z           | Col %        | z              | Col %        |
| Total             | 531   | 72.1          | 205           | 27.9           | 497        | 77.5          | 144         | 22.5       | 445      | 78.9          | 119            | 21.1           | 439         | 81.3        | 101            | 18.7          | 394         | 82.1         | 86             | 17.9         |
| Sex at Birth      |       |               |               |                |            |               |             |            |          |               |                |                |             |             |                |               |             |              |                |              |
| Female            | 148   | 76.3          | 46            | 23.7           | 06         | 73.2          | 33          | 26.8       | 88       | 75.2          | 29             | 24.8           | 94          | 80.3        | 23             | 19.7          | 100         | 85.5         | 17             | 14.5         |
| Male              | 383   | 70.7          | 159           | 29.3           | 407        | 78.6          | 111         | 21.4       | 357      | 79.9          | 06             | 20.1           | 345         | 81.6        | 78             | 18.4          | 294         | 81.0         | 69             | 19.0         |
| Race/Ethnicity    |       |               |               |                |            |               |             |            |          |               |                |                |             |             |                |               |             |              |                |              |
| Black             | 370   | 72.3          | 142           | 27.7           | 376        | 78.7          | 102         | 21.3       | 293      | 76.9          | 88             | 23.1           | 319         | 81.2        | 74             | 18.8          | 252         | 81.6         | 57             | 18.4         |
| Hispanic          | 81    | 73            | 30            | 27.0           | 59         | 83.1          | 12          | 16.9       | 65       | 89.0          | 00             | 11.0           | 65          | 86.7        | 10             | 13.3          | 78          | 84.8         | 14             | 15.2         |
| White             | 69    | 75            | 23            | 25.0           | 47         | 69.1          | 21          | 30.9       | 70       | 81.4          | 16             | 18.6           | 46          | 82.1        | 10             | 17.9          | 52          | 81.3         | 12             | 18.8         |
| Asian             | 9     | *             | *             | *              | 7          | 53.8          | 9           | 46.2       | 10       | *             | *              | *              | *           | *           | 9              | *             | Ø           | *            | *              | *            |
| Multi-race        | *     | *             | *             | *              | *          | *             | *           | *          | *        | *             | *              | *              | *           | *           | *              | *             | *           | 100          | 0              | 0            |
| Other/Unknown     | *     | *             | *             | *              | *          | *             | *           | *          | *        | *             | *              | *              | *           | 100         | 0              | 0             | *           | *            | *              | *            |
| Age at HIV Dx     |       |               |               |                |            |               |             |            |          |               |                |                |             |             |                |               |             |              |                |              |
| 0-12              | *     | 100           | 0             | 0              | *          | 100           | 0           | 0          | *        | 100           | 0              | 0              | *           | 100         | 0              | 0             | 0           | 0            | 0              | 0            |
| 13-19             | 30    | *             | *             | *              | 43         | *             | *           | *          | 30       | *             | ×              | *              | 33          | *           | *              | *             | 27          | *            | *              | *            |
| 20-24             | 125   | 80.6          | 30            | 19.4           | 112        | 84.8          | 20          | 15.2       | 101      | 91.8          | 6              | 8.2            | 95          | *           | *              | *             | 78          | 90.7         | 00             | 9.3          |
| 25-29             | 91    | 79.8          | 23            | 20.2           | 83         | 81.4          | 19          | 18.6       | 77       | 88.5          | 10             | 11.5           | 85          | 88.5        | 11             | 11.5          | 85          | 85.9         | 14             | 14.1         |
| 30-39             | 106   | 72.1          | 41            | 27.9           | 94         | 73.4          | 34          | 26.6       | 06       | 74.4          | 31             | 25.6           | 103         | 78.6        | 28             | 21.4          | 93          | 83.8         | 18             | 16.2         |
| 40-49             | 66    | 64.3          | 55            | 35.7           | 84         | 71.8          | 33          | 28.2       | 64       | 67.4          | 31             | 32.6           | 58          | 67.4        | 28             | 32.6          | 47          | 69.1         | 21             | 30.9         |
| 50+               | 79    | 60.3          | 52            | 39.7           | 76         | 67.9          | 36          | 32.1       | 82       | 68.9          | 37             | 31.1           | 63          | 68.5        | 29             | 31.5          | 64          | 73.6         | 23             | 26.4         |
| Transmission Risk |       |               |               |                |            |               |             |            |          |               |                |                |             |             |                |               |             |              |                |              |
| MSM               | 225   | 74            | 79            | 26.0           | 267        | 81.7          | 60          | 18.3       | 247      | 85.8          | 41             | 14.2           | 258         | 83.5        | 51             | 16.5          | 229         | 84.8         | 41             | 15.2         |
| PWID              | 64    | 77.1          | 19            | 22.9           | 33         | 78.6          | 6           | 21.4       | 33       | 82.5          | 7              | 17.5           | 28          | *           | *              | *             | 24          | *            | *              | *            |
| Heterosexual      | 214   | 69            | 96            | 31.0           | 177        | 70.8          | 73          | 29.2       | 154      | 69.1          | 69             | 30.9           | 143         | 76.5        | 44             | 23.5          | 123         | 75.9         | 39             | 24.1         |
| MSM/PWID          | 6     | *             | *             | *              | 00         | *             | *           | *          | 9        | 100           | 0              | 0              | *           | *           | *              | *             | *           | *            | *              | *            |
| Pediatric         | *     | 100           | 0             | 0              | 9          | 100           | 0           | 0          | *        | 100           | 0              | 0              | *           | 100         | 0              | 0             | 0           | 0            | 0              | 0            |
| No Risk Reported  | 18    | 64.3          | 10            | 35.7           | 9          | *             | *           | *          | *        | *             | *              | *              | 7           | *           | *              | *             | 14          | *            | *              | *            |
|                   | Note  | s *Cells s    | size < 6 aı   | re suppres     | sed. Cor   | ncurrent H    | 4IV/AIDS    | is defined | as diagn | iosis of      |                |                |             |             |                |               |             |              |                |              |
|                   |       | AIDS w        | /ithin 90     | days of ini    | tial diagr | nosis of H    |             |            | )        |               |                |                |             |             |                |               |             |              |                |              |

HIV Surveillance Report, Philadelphia September 2017 | 15

TABLE 5

#### Incidence Estimates by Year and Selected Charateristics | 2013-2015

|                        |     |            | 2013           |              |           |             | 2014          |              |           |              | 2015            |        |
|------------------------|-----|------------|----------------|--------------|-----------|-------------|---------------|--------------|-----------|--------------|-----------------|--------|
|                        | Ν   | %          | 95% CI         | Rate†        | Ν         | %           | 95% CI        | Rate†        | N         | %            | 95% CI          | Rate†  |
| Total                  | 497 | 100%       | 323-671        | 32.6         | 328       | 100%        | 217-439       | 21.5         | 372       | 100%         | 205-393         | 24.4   |
| Sex at Birth           |     |            |                |              |           |             |               |              |           |              |                 |        |
| Male                   | 418 | 84.1%      | 261-575        | 58.1         | 263       | 80.2%       | 170-356       | 36.5         | 320       | 86%          | 215-424         | 44.5   |
| Female                 | 79  | 15.9%      | 18-141         | 9.8          | 65        | 19.8%       | 15-115        | 8.1          | 52        | 14%          | 26-79           | 6.5    |
| Race/Ethnicity         |     | -          |                |              |           |             |               |              |           |              |                 |        |
| Black                  | 387 | 77.9%      | 238-535        | 60.1         | 183       | 55.8%       | 106-261       | 28.4         | 265       | 71.2%        | 175-355         | 41.1   |
| White                  | 68  | 13.7%      | 16-120         | 12.1         | 55        | 16.8%       | 19-90         | 9.8          | 56        | 15.1%        | 18-95           | 10.0   |
| Hispanic               | 38  | 7.6%       | 0-78           | 20.3         | 84        | 25.6%       | 29-139        | 44.8         | 44        | 11.8%        | 11-76           | 23.5   |
| Other                  | 4   | 0.8%       | 0-18           | 3.9          | 6         | 1.8%        | 0-17          | 5.8          | 7         | 1.9%         | 0-20            | 6.8    |
| Age at Infection       |     |            |                |              |           |             |               |              |           |              |                 |        |
| 13-24                  | 195 | 39.2%      | 101-290        | 65.7         | 126       | 38.4%       | 68-185        | 41.8         | 158       | 42.5%        | 90-227          | 52.4   |
| 25-34                  | 133 | 26.8%      | 55-211         | 54.1         | 90        | 27.4%       | 42-138        | 36.6         | 127       | 34.1%        | 69-185          | 51.6   |
| 35-44                  | 81  | 16.3%      | 23-139         | 43.0         | 41        | 12.5%       | 5-77          | 21.8         | 45        | 12.1%        | 12-79           | 23.9   |
| 45+                    | 87  | 17.5%      | 26-148         | 16.0         | 71        | 21.6%       | 16-127        | 13.1         | 42        | 11.3%        | 12-72           | 7.7    |
| Transmission Risk      |     |            |                |              |           |             |               |              |           |              |                 |        |
| MSM                    | 304 | 61.2%      | 174-434        | 1118.7       | 173       | 52.7%       | 106-241       | 640.1        | 284       | 76.3%        | 183-384         | 1047.9 |
| PWID                   | 31  | 6.2%       | 0-67           | 142.1        | 41        | 12.5%       | 0-95          | 186.3        | 13        | 3.5%         | 2-25            | 59.3   |
| Heterosexual/<br>Other | 162 | 32.6%      | 75-249         | 61.8         | 108       | 32.9%       | 38-177        | 41.2         | 75        | 20.2%        | 42-108          | 28.6   |
| TOTAL Number           | N - |            | 197            |              |           | number of   | 328           |              |           |              | 372             | Due    |
|                        | No  | tes *Incid | ence of diseas | se is define | ed as the | number of I | new infectior | ns in a give | en time p | eriod, typic | cally one year. | Due    |

\*Incidence of disease is defined as the number of new infections in a given time period, typically one year. Due to the nature of HIV infection, true incidence is difficult to measure. Recent infection is rarely accompanied with symptoms, and persons are often unaware of their exposure. Routine testing of all persons at risk for HIV is sporadic at best, and many are not tested and diagnosed until some time after their initial infection. The estimates presented here utilize diagnostic testing algorithms designed to detect recent infection, along with testing and treatment history data available for newly diagnosed persons in Philadelphia. These estimates provide the best available indicator of the true number of new HIV infections in Philadelphia. While the rate of incident cases is declining amongst most groups, new HIV transmissions are still affecting certain groups disproportionately. Blacks and Hispanics, males, those aged 13-24, 25-34, and the MSM population are all experiencing the highest percentages of new HIV infections.

† Rate of incident cases are per 100,000 people and based on 2010 decennial census

# AIDS Diagnoses

#### TABLE 6

#### By Year and Selected Characteristics | 2012-2016

| Dev even be       |                 |       |       |     | Y     | EAR O | F DIAGN | OSIS |       |     |       |
|-------------------|-----------------|-------|-------|-----|-------|-------|---------|------|-------|-----|-------|
| indicate 2016     |                 |       | 2012  |     | 2013  |       | 2014    |      | 2015  | 2   | 2016  |
| percentages       |                 | Ν     | %     | Ν   | %     | Ν     | %       | Ν    | %     | Ν   | %     |
|                   | Total           | 428   | 100%  | 351 | 100%  | 266   | 100%    | 242  | 100%  | 206 | 100%  |
| Sex at Birth      |                 |       |       |     |       |       |         |      |       |     |       |
|                   | Female          | 129   | 30.1% | 99  | 28.2% | 83    | 31.2%   | 71   | 29.3% | 64  | 31.0% |
|                   | Male            | 299   | 69.8% | 252 | 71.7% | 183   | 68.7%   | 171  | 70.6% | 142 | 68.9% |
| Race/Ethnicity    |                 |       |       |     |       |       |         |      |       |     |       |
|                   | Black           | 299   | 69.8% | 248 | 70.6% | 192   | 72.1%   | 180  | 74.3% | 142 | 68.9% |
|                   | Hispanic        | 64    | 14.9% | 47  | 13.3% | 28    | 10.5%   | 32   | 13.2% | 33  | 16.0% |
|                   | White           | 52    | 12.1% | 38  | 10.8% | 34    | 12.7%   | 22   | 9.0%  | 25  | 12.1% |
|                   | Multi-race      | *     | *     | 9   | 2.5%  | 9     | 3.3%    | *    | *     | *   | *     |
|                   | Asian           | 7     | 1.6%  | 8   | 2.2%  | *     | *       | *    | *     | *   | *     |
|                   | Other/Unknow    | n *   | *     | *   | *     | *     | *       | *    | *     | *   | *     |
| Age Category      |                 |       |       |     |       |       |         |      |       |     |       |
|                   | 13-19           | 9     | 2.1%  | *   | *     | *     | *       | 6    | 2.4%  | *   | *     |
|                   | 20-24           | 48    | 11.2% | 38  | 10.8% | 15    | 5.6%    | 13   | 5.3%  | 14  | 6.7%  |
|                   | 25-29           | 46    | 10.7% | 44  | 12.5% | 29    | 10.9%   | 36   | 14.8% | 34  | 16.5% |
|                   | 30-39           | 93    | 21.7% | 81  | 23.0% | 64    | 24.0%   | 58   | 23.9% | 47  | 22.8% |
|                   | 40-49           | 118   | 27.5% | 83  | 23.6% | 75    | 28.1%   | 57   | 23.5% | 47  | 22.8% |
|                   | 50+             | 114   | 26.6% | 102 | 29.0% | 80    | 30.0%   | 72   | 29.7% | 61  | 29.6% |
| Transmission Risk |                 |       |       |     |       |       |         |      |       |     |       |
|                   | MSM             | 146   | 34.1% | 116 | 33.0% | 87    | 32.7%   | 97   | 40.0% | 79  | 38.3% |
|                   | PWID            | 74    | 17.2% | 46  | 13.1% | 40    | 15.0%   | 36   | 14.8% | 16  | 7.7%  |
|                   | Heterosexual    | 182   | 42.5% | 170 | 48.4% | 131   | 49.2%   | 98   | 40.4% | 101 | 49.0% |
|                   | MSM/PWID        | 9     | 2.1%  | *   | *     | *     | *       | *    | *     | *   | *     |
|                   | Pediatric       | *     | *     | 0   | 0     | *     | *       | *    | *     | *   | *     |
|                   | No Risk Reporte | ed 16 | 3.7%  | 15  | 4.2%  | 6     | 2.2%    | *    | *     | *   | *     |
|                   |                 |       | -     |     |       |       |         |      |       |     |       |
|                   |                 |       |       |     |       |       |         |      |       |     |       |
|                   |                 |       |       |     |       |       |         |      |       |     |       |
|                   |                 |       |       |     |       |       | Ţ       |      |       |     | -•    |
|                   |                 |       |       |     |       |       |         |      |       |     |       |
| TOTAL CASES       |                 | 4     | 28    |     | 351   |       | 266     |      | 242   |     | 206   |

**Notes** \*Cells size < 6 are suppressed.

A proportion of AIDS diagnoses in each year were diagnosed with HIV in a previous year and later progressed to AIDS.

# AIDS Diagnoses

#### FIGURE 2 Philadelphia HIV and AIDS Diagnoses, Deaths, and People Living with HIV/AIDS by Year | 1985-2016



#### FIGURE 3

#### Rates of Newly Diagnosed HIV/AIDS per 100,000 People by Year of Diagnosis and Risk Group | 2010-2016

MSM population size based on estimates of MSM activity among males 13 and older in the last 5 years. PWID population size based on estimate of 173 active injection drug users per 10,000 population. High risk heterosexual population includes all individuals 18 and older living below poverty level.



|                 | TABLE 7<br>HIV (non                   | -AIDS)       | and A     | IDS Ca                         | ses by Se                        | lected                 | Charac      | teristics | 2016  |   |
|-----------------|---------------------------------------|--------------|-----------|--------------------------------|----------------------------------|------------------------|-------------|-----------|-------|---|
|                 |                                       | HIV (N       | ON-AII    | 25)                            | А                                |                        |             | HIV       | AIDS  |   |
|                 |                                       | N            | %         |                                | N                                | %                      |             | N         | %     |   |
|                 | Total                                 | 8,324        | 100%      |                                | 10,789                           | 100%                   |             | 19,113    | 100%  |   |
| Sex at Birth    |                                       | ,            |           |                                | ,                                |                        |             | ,         |       |   |
| •               | Female                                | 2,382        | 28.6%     |                                | 2,996                            | 27.7%                  |             | 5,378     | 28.1% |   |
| •               | Male                                  | 5,942        | 71.3%     |                                | 7,793                            | 72.2%                  |             | 13,735    | 71.8% | 0 |
| Race/Ethnicity  |                                       |              |           |                                |                                  |                        |             |           |       |   |
|                 | Black                                 | 5,245        | 63.0%     |                                | 6,963                            | 64.5%                  |             | 12,208    | 63.8% |   |
|                 | White                                 | 1,462        | 17.5%     |                                | 1,908                            | 17.6%                  |             | 3,370     | 17.6% |   |
|                 | Hispanic                              | 1,339        | 16.0%     |                                | 1,554                            | 14.4%                  |             | 2,893     | 15.1% |   |
|                 | Multi-race                            | 160          | 1.9%      |                                | 246                              | 2.2%                   |             | 406       | 2.1%  |   |
|                 | Asian                                 | 93           | 1.1%      |                                | 96                               | 0.8%                   |             | 189       | 0.9%  |   |
|                 | Other/Unknow                          | wn 25        | 0.3%      |                                | 22                               | 0.2%                   |             | 47        | 0.2%  |   |
| Age Category†   |                                       |              |           |                                | 1 1                              |                        |             |           |       |   |
|                 | Unknown                               | 35           | 0.4%      |                                | 73                               | 0.6%                   |             | 108       | 0.5%  |   |
|                 | 0-12                                  | 24           | 0.2%      |                                | *                                | *                      |             | 29        | 0.1%  |   |
|                 | 13-19                                 | 74           | 0.8%      |                                | 23                               | 0.2%                   |             | 97        | 0.5%  |   |
|                 | 20-24                                 | 394          | 4.7%      |                                | 92                               | 0.8%                   |             | 486       | 2.5%  |   |
|                 | 25-29                                 | 943          | 11.3%     |                                | 402                              | 3.7%                   |             | 1,345     | 7.0%  |   |
|                 | 30-39                                 | 1,941        | 23.3%     |                                | 1,179                            | 10.9%                  |             | 3,120     | 16.3% |   |
|                 | 40-49                                 | 1,832        | 22.0%     |                                | 2,380                            | 22.0%                  |             | 4,212     | 22.0% |   |
|                 | 50+                                   | 3,081        | 37.0%     |                                | 6,635                            | 61.4%                  |             | 9,716     | 50.8% |   |
| ansmission Risk |                                       |              |           |                                |                                  |                        |             |           |       |   |
|                 | MSM                                   | 3,362        | 40.3%     |                                | 3,591                            | 33.2%                  |             | 6,953     | 36.3% |   |
|                 | PWID                                  | 1,381        | 16.5%     |                                | 2,837                            | 26.2%                  |             | 4,218     | 22.0% |   |
|                 | Heterosexual                          | 3,052        | 36.6%     |                                | 3,584                            | 33.2%                  |             | 6,636     | 34.7% |   |
|                 | MSM/PWID                              | 169          | 2.0%      |                                | 413                              | 3.8%                   |             | 582       | 3.0%  |   |
|                 | Pediatric                             | 128          | 1.5%      |                                | 146                              | 1.3%                   |             | 274       | 1.4%  |   |
|                 | Other                                 | *            | *         |                                | 10                               | 0.0%                   |             | 14        | 0.0%  |   |
|                 | No Risk Repor                         | ted 228      | 2.7%      |                                | 208                              | 1.9%                   |             | 436       | 2.2%  |   |
|                 | <ul><li>FEMALE</li><li>MALE</li></ul> | 8            | ,324      |                                | 10                               | ,789                   |             | 19,       | ,113  |   |
| Total N         |                                       | HIV (N       | ON-AII    | DS)                            | A                                | IDS                    |             | HIV       | AIDS  |   |
|                 | Notes * Cell                          | sizes <6 are | supressed | d. † Age as o<br>If Public Hea | of December 3<br>alth. AIDS Acti | 1, 2016<br>vities Coor | dinating Of | ice       |       |   |

TABLE 8

#### By Race/Ethnicity and Selected Characteristics | 2016

|                   |                                       |  | BLA       | СК    |         |        |                     | WHI.       | ГΕ |   |       | HISPA | NIC |  |
|-------------------|---------------------------------------|--|-----------|-------|---------|--------|---------------------|------------|----|---|-------|-------|-----|--|
|                   |                                       | Ν  | %         |       |         |        | Ν                   | %          |    |   | Ν     | %     |     |  |
|                   | Total                                 | 12,208   | 100%      |       |         |        | 3,370               | 100%       |    |   | 2,893 | 100%  |     |  |
| Sex at Birth      |                                       |  |           |       |         |        |                     |            |    |   |       |       |     |  |
| •                 | Female                                | 3,918  | 32.0%     |       |         |        | 509                 | 15.1%      |    |   | 778   | 26.8% |     |  |
| •                 | Male                                  | 8,290  | 67.9%     |       |         |        | 2,861               | 84.8%      | U  |   | 2,115 | 73.1% |     |  |
| Age Category†     |                                       |  |           |       |         |        |                     |            |    |   |       |       |     |  |
|                   | Unknown                               | 65   | 0.5%      |       |         |        | 13                  | 0.3%       |    |   | 25    | 0.8%  |     |  |
|                   | 0-12                                  | 22   | 0.1%      |       |         |        | 0                   | 0.0%       |    |   | k     | *     |     |  |
|                   | 13-19                                 | 81   | 0.6%      |       |         |        | *                   | *          |    |   | 1     | 0.3%  |     |  |
|                   | 20-24                                 | 379  | 3.1%      |       |         |        | 29                  | 0.8%       |    |   | 68    | 2.3%  |     |  |
|                   | 25-29                                 | 987  | 8.0%      |       |         |        | 124                 | 3.6%       |    |   | 182   | 6.2%  |     |  |
|                   | 30-39                                 | 2,014  | 16.4%     |       |         |        | 461                 | 13.6%      |    |   | 50    | 17.3% |     |  |
|                   | 40-49                                 | 2,651  | 21.7%     |       |         |        | 670                 | 19.8%      |    |   | 720   | 24.8% |     |  |
|                   | 50+                                   | 6,009  | 49.2%     |       |         |        | 2,070               | 61.4%      |    |   | 1,381 | 47.7% |     |  |
| Transmission Risk |                                       |  |           |       |         |        |                     |            |    |   |       |       |     |  |
|                   | MSM                                   | 3,924  | 32.1%     |       |         |        | 1,998               | 59.2%      |    |   | 773   | 26.7% |     |  |
|                   | PWID                                  | 2,529  | 20.7%     |       |         |        | 611                 | 18.1%      |    |   | 959   | 33.1% |     |  |
|                   | Heterosexual                          | 4,919  | 40.2%     |       |         |        | 540                 | 16.0%      |    |   | 944   | 32.6% |     |  |
|                   | MSM/PWID                              | 342  | 2.8%      |       |         |        | 145                 | 4.3%       |    |   | 77    | 2.6%  |     |  |
|                   | Pediatric                             | 197  | 1.6%      |       |         |        | 22                  | 0.6%       |    |   | 5     | 1.7%  |     |  |
|                   | Other                                 | 7  | 0.0%      |       |         |        | *                   | *          |    |   | k     | *     |     |  |
|                   | No Risk Reporte                       | ed 290   | 2.3%      |       |         |        | 49                  | 1.4%       |    |   | 88    | 3.0%  |     |  |
|                   | <ul><li>FEMALE</li><li>MALE</li></ul> |  | 12,2      | 08    | İ       |        |                     |            |    | į |       |       |     |  |
| Total N           |                                       |  |           |       |         |        |                     | 3,37       | C  |   |       | 2,89  | 93  |  |
|                   | Notes *Calles                         | 1705 26 250  | BLA       | CK    | 10.26.2 | of Doo | ombor <sup>31</sup> | <b>WHI</b> | TE |   |       | HISPA | NIC |  |
|                   | Notes Cell s                          | izes <o are<="" td=""><td>supressed</td><td>ı.⊺A§</td><td>ge as c</td><td>n Dec</td><td>ernber 3</td><td>1,∠010</td><td></td><td></td><td></td><td></td><td></td><td></td></o> | supressed | ı.⊺A§ | ge as c | n Dec  | ernber 3            | 1,∠010     |    |   |       |       |     |  |

#### TABLE 9

#### By Sex at Birth and Selected Characteristics | 2016

|                  |                  |                                | FEMALE                             |                                   |                            | MALE       |                   |  |
|------------------|------------------|--------------------------------|------------------------------------|-----------------------------------|----------------------------|------------|-------------------|--|
|                  |                  | N                              | %                                  |                                   | N                          | %          |                   |  |
|                  | Total            | 5,378                          | 100%                               |                                   | 13,735                     | 100%       |                   |  |
| Race/Ethnicity   |                  |                                |                                    |                                   |                            |            |                   |  |
|                  | Black            | 3,918                          | 72.8%                              |                                   | 8,290                      | 60.3%      |                   |  |
|                  | White            | 509                            | 9.4%                               |                                   | 2,861                      | 20.8%      |                   |  |
|                  | Hispanic         | 778                            | 14.4%                              |                                   | 2,115                      | 15.3%      |                   |  |
|                  | Multi-race       | 119                            | 2.2%                               |                                   | 287                        | 2.0%       |                   |  |
|                  | Asian            | 42                             | 0.7%                               |                                   | 147                        | 1.0%       |                   |  |
|                  | Other/Unknown    | 12                             | 0.2%                               |                                   | 35                         | 0.2%       |                   |  |
| Age Category†    |                  |                                | · · ·                              |                                   |                            |            | · · · · · · · ·   |  |
|                  | Unknown          | 32                             | 0.5%                               |                                   | 76                         | 0.5%       |                   |  |
|                  | 0-12             | 16                             | 0.2%                               |                                   | 13                         | 0.0%       |                   |  |
|                  | 13-19            | 31                             | 0.5%                               |                                   | 66                         | 0.4%       |                   |  |
|                  | 20-24            | 103                            | 1.9%                               |                                   | 383                        | 2.7%       |                   |  |
|                  | 25-29            | 250                            | 4.6%                               |                                   | 1,095                      | 7.9%       |                   |  |
|                  | 30-39            | 809                            | 15.0%                              |                                   | 2,311                      | 16.8%      |                   |  |
|                  | 40-49            | 1,477                          | 27.4%                              |                                   | 2,735                      | 19.9%      |                   |  |
|                  | 50+              | 2,660                          | 49.4%                              |                                   | 7,056                      | 51.3%      |                   |  |
| ransmission Risk |                  |                                |                                    |                                   |                            |            | · · · · · · · · · |  |
|                  | MSM              | -                              | -                                  |                                   | 6,953                      | 50.6%      |                   |  |
|                  | PWID             | 1,380                          | 25.6%                              |                                   | 2,838                      | 20.6%      |                   |  |
|                  | Heterosexual     | 3,687                          | 68.5%                              |                                   | 2,949                      | 21.4%      |                   |  |
|                  | MSM/PWID         | -                              | -                                  |                                   | 582                        | 4.2%       |                   |  |
|                  | Pediatric        | 132                            | 2.4%                               |                                   | 142                        | 1.0%       |                   |  |
|                  | Other            | *                              | *                                  |                                   | 11                         | 0.0%       |                   |  |
|                  | No Risk Reported | 176                            | 3.2%                               |                                   | 260                        | 1.8%       |                   |  |
|                  |                  |                                | 5.378                              |                                   |                            | 13,735     |                   |  |
| Total N          |                  |                                |                                    |                                   |                            |            |                   |  |
|                  |                  |                                | FEMALI                             | E                                 |                            | MALE       |                   |  |
|                  | Notes *Cell size | s <6 are supre<br>hia Departme | essed. † Age as<br>nt of Public He | of December 3<br>alth. AIDS Activ | l, 2016<br>ities Coordinat | ing Office |                   |  |

#### TABLE 10

## By Gender Identity and Selected Characteristics | 2016

|                   |                  |  |   | GENDER I  | DENTITY  |  |   |  |
|-------------------|------------------|--|---|---|--|--|---|--|
|                   | N                | lale   | Fen   | nale  | M<br>to Fe   | ale<br>emale   | Fer<br>to I                             | nale<br>Vale   |
|                   | N                | %  | N   | %   | Ν  | %  | Ν                                       | %  |
| Total             | 13,512           | 100%   | 5,360   | 100%  | 227  | 100%   | 10                                      | 100%   |
| Race/Ethnicity    |                  |  |   |   |  |  |   |  |
| Black             | 8,119            | 60.0%  | 3,903   | 72.8%   | 174  | 76.6%  | 8                                       | 80.0%  |
| White             | 2,844            | 21.0%  | 508   | 9.4%  | 17   | 7.4%   | *                                       | *  |
| Hispanic          | 2,090            | 15.4%  | 776   | 14.4%   | 26   | 11.4%  | *                                       | *  |
| Multi-race        | 282              | 2.0%   | 119   | 2.2%  | *  | *  | 0                                       | 0.0%   |
| Asian             | 143              | 1.0%   | 42  | 0.7%  | *  | *  | 0                                       | 0.0%   |
| Other/Unknown     | 34               | 0.2%   | 12  | 0.2%  | *  | *  | 0                                       | 0.0%   |
| Age Category†     |                  |  |   |   |  |  |   |  |
| Unknown           | 75               | 0.5%   | 32  | 0.5%  | *  | *  | 0                                       | 0.0%   |
| 0-12              | 13               | 0%   | 16  | 0.2%  | 0  | 0.0%   | 0                                       | 0.0%   |
| 13-19             | 65               | 0.4%   | 30  | 0.5%  | *  | *  | 0                                       | 0.0%   |
| 20-24             | 367              | 2.7%   | 104   | 1.9%  | 15   | 6.6%   | 0                                       | 0.0%   |
| 25-29             | 1,046            | 7.7%   | 245   | 4.5%  | 51   | 22.4%  | *                                       | *  |
| 30-39             | 2,232            | 16.5%  | 806   | 15.0%   | 78   | 34.3%  | *                                       | *  |
| 40-49             | 2,707            | 20.0%  | 1,472   | 27.4%   | 31   | 13.6%  | 0                                       | 0.0%   |
| 50+               | 7,007            | 51.8%  | 2,655   | 49.5%   | 49   | 21.5%  | *                                       | *  |
| Transmission Risk |                  |  |   |   |  |  |   |  |
| Sexual Contact    | 9,724            | 71.9%  | 3,675   | 68.5%   | 181  | 79.7%  | 8                                       | 80.0%  |
| PWID              | 3,376            | 24.9%  | 1,378   | 25.7%   | 42   | 18.5%  | *                                       | *  |
| Pediatric         | 142              | 1.0%   | 132   | 2.4%  | 0  | 0.0%   | 0                                       | 0.0%   |
| Other             | 11               | 0%   | *   | *   | 0  | 0.0%   | 0                                       | 0.0%   |
| No Risk Reported  | 259              | 1.9%   | 172   | 3.2%  | *  | *  | *                                       | *  |
| TOTAL N           | Notes *Ce<br>add | ,512<br>Male<br>ell sizes <6 are si<br>nder identity is o<br>ditional informat | 5,3<br>Fer<br>upressed. † Age<br>often not record<br>tion was present | 360<br>nale<br>e as of December<br>ed in medical rec<br>t. The prevalence | 2<br>Male t<br>31, 2016<br>cords. Birth se<br>among Male | 227<br>o Female<br>x was used to dete<br>to Female, Female | Femal<br>ermine gende<br>e to Male, and | 10<br>e to Male<br>r identity where<br>those cases w |

#### TABLE 11

#### Prevalence Rates by Sex and Race/Ethnicity | 2016

|                        | POPULATION | PLWHA  | <b>RATE PER 100,000</b> |  |
|------------------------|------------|--------|-------------------------|--|
| Sex                    |            |        |                         |  |
| Female                 | 806,193    | 5,378  | 667.1                   |  |
| Male                   | 719,813    | 13,735 | 1,908.1                 |  |
| Race/Ethnicity         |            |        |                         |  |
| Hispanic               | 187,611    | 2,893  | 1,542.0                 |  |
| Black                  | 644,287    | 12,208 | 1,894.8                 |  |
| White                  | 562,585    | 3,370  | 599.0                   |  |
| Asian                  | 95,521     | 189    | 197.9                   |  |
| AIAN                   | 3,498      | 35     | 1,000.6                 |  |
| NHPI                   | 457        | 11     | 2,407.0                 |  |
| Other Race             | 4,105      | *      | *                       |  |
| Multi-racial           | 27,942     | 406    | 1,453.0                 |  |
| Sex and Race/Ethnicity | /          |        |                         |  |
| Hispanic Female        | 94,484     | 778    | 823.4                   |  |
| Black Female           | 353,319    | 3,918  | 1,108.9                 |  |
| White Female           | 290,025    | 509    | 175.5                   |  |
| Asian Female           | 49,137     | 42     | 85.5                    |  |
| AIAN Female            | 1,882      | 9      | 478.2                   |  |
| NHPI Female            | 237        | *      | *                       |  |
| Other Race Female      | 2,014      | 0      | 0                       |  |
| Nultiracial Female     | 15,095     | 119    | 788.3                   |  |
| Hispanic Male          | 93,127     | 2,115  | 2,271.1                 |  |
| Black Male             | 290,968    | 8,290  | 2,849.1                 |  |
| White Male             | 272,560    | 2,861  | 1,049.7                 |  |
| Asian Male             | 46,384     | 147    | 316.9                   |  |
| AIAN Male              | 1,616      | 26     | 1,608.9                 |  |
| NHPI Male              | 220        | 8      | 3,636.4                 |  |
| Other Race Male        | 2,091      | *      | *                       |  |
| Multiracial Male       | 12,847     | 287    | 2,234.00                |  |
|                        |            |        |                         |  |
| Total                  | 1,526,006  | 19,113 | 1,252.5                 |  |



Notes \*MSM total population based on estimated number of active MSM in the past 5 years †PWID population estimated as 173 per 10,000 population ‡Population of individuals 18 and older living below poverty level
 Source Philadelphia Department of Public Health, AIDS Activities Coordinating Office





#### TABLE 12

## Cumulative Adult HIV (non-AIDS) Cases | 2016

|                   |  | HIV (N   | ON-41  | ואר | Δ      |       |   | HIV    |       |  |
|-------------------|--|----------|--------|-----|--------|-------|---|--------|-------|--|
|                   |  | N        | %      |     | N      | %     |   | N      | %     |  |
|                   | Total  | 8.826    | 100%   |     | 23.526 | 100%  |   | 32.352 | 100%  |  |
| Sex at Birth      |  | -,       |        |     | ,      |       |   | /      |       |  |
| •                 | Female   | 2,552    | 28.9%  |     | 5,669  | 24.0% |   | 8,221  | 25.4% |  |
| •                 | Male   | 6,274    | 71.0%  |     | 17,857 | 75.9% | 0 | 24,131 | 74.5% |  |
| Race/Ethnicity    |  |          |        |     |        |       |   | ,      |       |  |
|                   | Black  | 5,657    | 64.0%  |     | 15,340 | 65.2% |   | 20,997 | 64.9% |  |
|                   | White  | 1,621    | 18.3%  |     | 4,913  | 20.8% |   | 6,534  | 20.1% |  |
|                   | Hispanic   | 1,273    | 14.4%  |     | 2,706  | 11.5% |   | 3,979  | 12.2% |  |
|                   | Multi-race   | 157      | 1.7%   |     | 427    | 1.8%  |   | 584    | 1.8%  |  |
|                   | Asian  | 88       | 0.9%   |     | 116    | 0.4%  |   | 204    | 0.6%  |  |
|                   | Other/Unkno  | wn 30    | 0.3%   |     | 24     | 0.1%  |   | 54     | 0.1%  |  |
| Age Category†     |  |          |        |     |        |       |   |        |       |  |
|                   | Unknown  | 0        | 0.0%   |     | 2,573  | 10.9% |   | 2,573  | 7.9%  |  |
|                   | 13-19  | 525      | 5.9%   |     | 605    | 2.5%  |   | 1,130  | 3.4%  |  |
|                   | 20-24  | 1,430    | 16.2%  |     | 1,894  | 8.0%  |   | 3,324  | 10.2% |  |
|                   | 25-29  | 1,404    | 15.9%  |     | 3,086  | 13.1% |   | 4,490  | 13.8% |  |
|                   | 30-39  | 2,540    | 28.7%  |     | 7,574  | 32.1% |   | 10,114 | 31.2% |  |
|                   | 40-49  | 1,839    | 20.8%  |     | 5,075  | 21.5% |   | 6,914  | 21.3% |  |
|                   | 50+  | 1,088    | 12.3%  |     | 2,719  | 11.5% |   | 3,807  | 11.7% |  |
| Transmission Risk |  |          |        |     |        |       |   |        |       |  |
|                   | MSM  | 3,319    | 37.6%  |     | 8,261  | 35.1% |   | 11,580 | 35.7% |  |
|                   | PWID   | 1,758    | 19.9%  |     | 7,734  | 32.8% |   | 9,492  | 29.3% |  |
|                   | Heterosexual   | 3,341    | 37.8%  |     | 5,990  | 25.4% |   | 9,331  | 28.8% |  |
|                   | MSM/PWID   | 173      | 1.9%   |     | 1,104  | 4.6%  |   | 1,277  | 3.9%  |  |
|                   | Pediatric  | *        | *      |     | *      | *     |   | *      | *     |  |
|                   | Other  | *        | *      |     | 60     | 0.2%  |   | 65     | 0.2%  |  |
|                   | No Risk Repor  | rted 227 | 2.5%   |     | 376    | 1.5%  |   | 603    | 1.8%  |  |
| Total N           | <ul><li>FEMALE</li><li>MALE</li></ul>  | ٤        | 3,826  |     | 23     | ,526  |   | 32,    | 352   |  |
|                   |  | HIV (N   | ON-AII | DS) | A      | IDS   |   | HIV    | AIDS/ |  |
|                   | <b>Notes</b> *Cell sizes <6 are supressed. † Age as of December 31, 2016 <b>Source</b> Philadelphia Department of Public Health, AIDS Activities Coordinating Office |          |        |     |        |       |   |        |       |  |

#### TABLE 13

#### By Hepatitis B or C Coinfection and Selected Characteristics † | 2016

|                   | Hepatitis B/HIV |                    | Hepatitis C/HIV |               | HIV/A                | HIV/AIDS Total |               |        |
|-------------------|-----------------|--------------------|-----------------|---------------|----------------------|----------------|---------------|--------|
|                   | N               | Row %              | Ν               | Row%          | Ν                    | Row%           |               |        |
| Total             | 956             | 5.0%               | 3,386           | 17.7%         | 19,113               | 100%           |               |        |
| Sex at Birth      |                 |                    |                 |               |                      |                |               |        |
| Female            | 219             | 4.1%               | 988             | 18.4%         | 5,378                | 100%           |               |        |
| Male              | 737             | 5.4%               | 2,398           | 17.5%         | 13,735               | 100%           |               |        |
| Race/Ethnicity    |                 |                    |                 |               |                      |                |               |        |
| Black             | 666             | 5.5%               | 1,951           | 16.0%         | 12,208               | 100%           |               |        |
| White             | 135             | 4.0%               | 594             | 17.6%         | 3,370                | 100%           |               |        |
| Hispanic          | 112             | 3.9%               | 719             | 24.9%         | 2,893                | 100%           |               |        |
| Multi-race        | 23              | 5.7%               | 100             | 24.6%         | 406                  | 100%           |               |        |
| Asian             | 16              | 8.5%               | 19              | 10.1%         | 189                  | 100%           |               |        |
| Other/Unknown     | *               | *                  | *               | *             | 47                   | 100%           |               |        |
| Age Category      |                 |                    |                 |               |                      |                |               |        |
| Unknown           | *               | *                  | 42              | 38.9%         | 108                  | 100%           |               |        |
| 0-12              | 0               | 0.0%               | *               | *             | 29                   | 100%           |               |        |
| 13-19             | *               | *                  | 0               | 0.0%          | 97                   | 100%           |               |        |
| 20-24             | *               | *                  | 21              | 4.3%          | 486                  | 100%           |               |        |
| 25-29             | 26              | 1.9%               | 67              | 5.0%          | 1,345                | 100%           |               |        |
| 30-39             | 108             | 3.5%               | 350             | 11.2%         | 3,120                | 100%           |               |        |
| 40-49             | 243             | 5.8%               | 654             | 15.5%         | 4,212                | 100%           |               |        |
| 50+               | 572             | 5.9%               | 2,251           | 23.2%         | 9,716                | 100%           |               |        |
| Transmission Risk |                 |                    |                 |               |                      |                |               |        |
| MSM               | 359             | 5.2%               | 515             | 7.4%          | 6,953                | 100%           |               |        |
| PWID              | 263             | 6.2%               | 1,758           | 41.7%         | 4,218                | 100%           |               |        |
| Heterosexual      | 278             | 4.2%               | 852             | 12.8%         | 6,636                | 100%           |               |        |
| MSM/PWID          | 32              | 5.5%               | 188             | 32.3%         | 582                  | 100%           |               |        |
| Pediatric         | 7               | 2.6%               | 11              | 4.0%          | 274                  | 100%           |               |        |
| Other             | 0               | 0.0%               | 7               | 50.0%         | 14                   | 100%           |               |        |
| No Risk Reported  | 17              | 3.9%               | 55              | 12.6%         | 436                  | 100%           |               |        |
|                   |                 | 5                  | 000             |               | 10,000               |                | 15,000        | 20,000 |
|                   |                 | -                  | ,<br>           |               | 1                    | Ц              |               | 10 112 |
|                   |                 |                    |                 |               |                      |                | TV/AIDS TOTAL | 19,113 |
|                   | Нер С,          | /HIV: 3,386        | 5               |               |                      |                |               |        |
|                   | Не              | p B/HIV: <b>95</b> | 6               |               |                      |                |               |        |
| TOTAL N           |                 |                    |                 |               |                      |                |               |        |
|                   | Notes           | *Cells size < 6 ar | e suppressed. ‡ | Row, not colu | ımn, percentages are | presented h    | ere           |        |

Source Philadelphia Department of Public Health, AIDS Activities Coordinating Office; Philadelphia Department of Public Health, Division of Disease Control, Viral Hepatitis Program

# Perinatal Exposures

#### TABLE 14

#### By Selected Demographics and Clinical Characteristics | 2012-2016

Perinatal exposures represent instances where HIV transmission might have occurred from mother to child during pregnancy, labor and delivery (L&D), or breastfeeding. Incidence of HIV infection among perinatally exposed children in Philadelphia has remained low in the past five years due to local perinatal prevention efforts. Clinical characteristics table shows data for the mother and child before, during, and after birth. Maternal viral load represents the most recent viral load before birth; prenatal care was defined as at least 1 medical visit during pregnancy; maternal timing at diagnosis was categorized as early (any time before L&D), late (during or after L&D), and unknown.

#### MATERNAL DEMOGRAPHICS

Ν % Maternal Age 13-19 5.2% 14 20-24 19.6% 53 25-34 145 53.7% ≥35 58 21.5% **Maternal Race** Black 217 80.4% White 20 7.4% Hispanic 27 10.0% Other 6 2.2% **Transmission Risk** Heterosexual 212 78.5% PWID 27 10.0% Pediatric 17 6.3% Other/Unk 14 5.2% **TOTAL N** 270

| Notes | Cells size < 6 are suppressed for demographic data but |
|-------|--|
|       | not clinical data.                                     |

Source Philadelphia Department of Public Health, AIDS Activities Coordinating Office

#### CLINICAL CHARACTERISTICS

|                     | NOT | INFECTED | HIV-INFECTED |        |  |
|---------------------|-----|----------|--------------|--------|--|
|                     | Ν   | %        | Ν            | %      |  |
| Maternal Viral Load |     |          |              |        |  |
| <1000               | 214 | 81.3%    | 4            | 57.1%  |  |
| ≥1000               | 40  | 15.2%    | 3            | 42.8%  |  |
| Unknown             | 9   | 3.4%     | 0            | 0.0%   |  |
| Prenatal care       |     |          |              |        |  |
| No                  | 62  | 23.5%    | 1            | 14.2%  |  |
| Yes                 | 201 | 76.4%    | 6            | 85.7%  |  |
| Unknown             | 0   | 0.0%     | 0            | 0.0%   |  |
| Maternal Timing     |     |          |              |        |  |
| of Diagnosis        |     |          |              |        |  |
| Early               | 267 | 100.0%   | 7            | 100.0% |  |
| Late                | 0   | 0.0%     | 0            | 0.0%   |  |
| Unknown             | 0   | 0.0%     | 0            | 0.0%   |  |
| ARV medications     |     |          |              |        |  |
| during pregnancy    |     |          |              |        |  |
| No                  | 7   | 2.6%     | 1            | 14.2%  |  |
| Yes                 | 182 | 69.2%    | 5            | 71.4%  |  |
| Unknown             | 74  | 28.1%    | 1            | 14.2%  |  |
| ARV medications     |     |          |              |        |  |
| during L&D          |     |          |              |        |  |
| No                  | 41  | 15.5%    | 0            | 0.0%   |  |
| Yes                 | 139 | 52.8%    | 6            | 85.7%  |  |
| Unknown             | 83  | 31.5%    | 1            | 14.2%  |  |
| Neonatal ARV        |     |          |              |        |  |
| medications         |     |          |              |        |  |
| No                  | 0   | 0.0%     | 0            | 0.0%   |  |
| Yes                 | 252 | 95.8%    | 7            | 100.0% |  |
| Unknown             | 11  | 4.1%     | 0            | 0.0%   |  |
| TOTAL N             |     | 263      |              | 7      |  |

# Reporting Information

#### Who Must Report?

All HIV Testing Providers, Health Care Providers & Laboratories

#### What Test Results Must Be Reported?

- All results, including: Positive, Negative & Indeterminate will be reported to the PDPH including if the patient is determined to have either:
  - a confirmed HIV infection
  - a probable or possible HIV infection (including cases where additional testing is needed to confirm the diagnosis)
- Preliminary Positive Results including instances where no supplemental/confirmatory testing was performed or when supplemental/confirmatory testing was negative
- Negative and indeterminate Results including test results for HIV infection within 180 days of (before, after, or on the same date as) the HIV diagnosis. The negative/indeterminate test results are needed to recognize infections as early or acute when transmission to others is more likely and intervention is more urgent.
- Results of all CD4 counts and HIV viral loads including undetectable results
- HIV genotype sequence data (FASTA or FASTQ format)

#### What Cases Need to be Reported?

- All individuals who are Philadelphia residents AND
- All individuals who are tested in Philadelphia or receive care at a Philadelphia based facility or provider.
- Pregnancy in an HIV-infected woman
- New HIV-positive result in a pregnant woman
- Birth of an infant to an HIV-infected woman

#### When Do I Need to Report?

The following tests results or events need to be reported by telephone to the PDPH within 1 business day of the result or the confirmation of the event:

- 1. Confirmed or suspected acute HIV infection (*Call 215-685-4781 to report a case*)
- 2. Pregnancy in an HIV-infected pregnant woman (*Call 215-685-4786 to report a case*)
- 3. New HIV-positive result in a pregnant woman (*Call 215-685-4786 to report a case*)
- 4. Birth of an infant to an HIV-infected woman (*Call 215-685-4786 to report a case*)

All other test results and HIV case reports must be reported to the PDPH within 5 business days of the receipt.

#### How Do I Submit a Report?

Drop off or mail the completed HIV Case Report Forms to the Philadelphia Health Department. To drop off the forms, put them in a sealed envelope and bring them to:

PDPH HIV Surveillance Unit 1101 Market Street, 8th floor, behind elevator C.

Call to drop off forms or for reporting questions: Maura Boughter-Dornfeld (215-685-4775) or Melissa Miller (215-685-4781).

Do not leave forms with the receptionist.

If you would like to mail the forms please use these steps:

1. Place the forms in a sealed envelope that states:

Confidential, to be opened by addressee only

2. Place the first envelope into another sealed envelope addressed to:

Philadelphia Health Department Attention: Maura Boughter-Dornfeld P.O. Box 58909 Philadelphia, PA 19102-8909

#### TO OUR READERS:

The AACO Surveillance Unit of the Philadelphia Department of Public Health, which conducts HIV/AIDS surveillance for the City of Philadelphia, produces this report. The data in this report reflects cases diagnosed through December 2016 and reported through June 2017.

HIV/AIDS surveillance is the ongoing and systematic collection, analysis, and dissemination of populationbased information on HIV/AIDS. There are two basic types of surveillance; active and passive. Passive surveillance is submission of HIV case reports from physicians, laboratories, and other individuals or institutions without having to regularly contact the reporting sources. Active surveillance employs strategies intended to identify unreported cases, and depends on secondary information sources for leads e.g., hospitals, clinics, physician offices, laboratories. Review of medical charts at provider sites or via telephone with facility staff are completed to establish cases of HIV infection and to obtain information critical to completing HIV case reports.

The HIV/AIDS case count in Philadelphia results from a combination of active and passive surveillance. Physicians began reporting AIDS cases to the Department of Health in 1983. Name-based HIV reporting began in October, 2005.

New HIV reporting regulations were approved by the City of Philadelphia's Board of Health in November 2016 and went into effect in January of 2017.

Any questions about this report and/or requests for data can be directed to:

#### Tanner Nassau, MPH AACOEPI@PHILA.GOV

Please allow at least 10 business days for all data requests.











